Additional approaches against neurodegenerative diseases have been recently reported, which often use specific peptides to target neurotoxic aggregates, e.g., of Aβ or α-syn [48,49]; though these approaches are out of the scope of the present paper, we briefly refer here to humanin (HN), as an indicative example of neurotherapeutic peptides that may prevent Aβ aggregation. This evidence concerns the gene MT-RNR2 and neurodegenerative disease.